Jerfiz

Clinical scientist/writer with a passion for communicating medical oncology breakthroughs and insights

[Jerfiz @Jerfiz1]

Join us this Friday, in San Diego, together with Catherine M. Broome, MD, @DevaSharma1981, and @DingliMD for an interactive symposia on the latest data on the diagnosis and management of cold agglutinin disease (CAD).
Register here: https://t.co/odYzpugXhP

[rcoledude @rcoledude]

Shout out to the MIRASOL team and GOG-Partners leadership and investigators for a successful phase 3 trial in recurrent platinum non-amenable ovarian cancer. First trial in this setting to improve OS along with PFS and 3x improvement in ORR. Should lead to rapid regular approval

[Jerfiz @Jerfiz1]

@rcoledude Fantastic news. Congrats!

[Jerfiz @Jerfiz1]

Truly amazing data!

[NEJM @NEJM]

#SGOMtg: A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo. Read full results of RUBY trial: https://t.co/w5JgJbEcoq

[Shannon Westin, MD, MPH, FASCO @ShannonWestin]

👏🙌NRG GY018!! We did it - improved progression free survival in MMRd AND MMRp #EndometrialCancer. Standard of care == CHANGED! #SGOMtg #gyncsm #ImmunoOnc Congrats to @NRGonc

[Rachna Shroff, MD, MS, FASCO @rachnatshroff]

Was it a LEAP of faith?? Final results from LEAP-002 with Lenva/Pembro in #HCC. Negative study - OS at 21.2 mths with higher than expected OS for Lenva alone. Kicking off the #GI session @myESMO @DrAngelaLamarca

[Jerfiz @Jerfiz1]

@GCC_Cortes Most impressive. Definitely setting a high-bar!

[Jordi Remon @JordiRemon]

Amivantamab and movocertinib approved in 2nd line EGFR ex20ins NSCLC. CLN 081 a new player!! 👏🏻👏🏻Promising activity (mPFA 10 months) with good safety profile and opening potential opportunities for sequential treatment approaches on this disease #ASCO2022

[BJ Rimel @BJRimelMD]

Exciting news from KEYNOTE 777 presented by Dr. Makker at #IGCS2021

[Jerfiz @Jerfiz1]

Cemiplimab a new standard in advanced cervical cancer?
#IGCS2021

[Vincent Rajkumar @VincentRK]

The vaccines are working.

[GvHD Hub @gvhd_hub]

CONGRESS | #ASH20 | Practice-changing clinical trial | Positive findings from the phase III REACH3 study reported by Robert Zeiser, @Klinik_Freiburg, showing superiority of ruxolitinib vs BAT in patients with SR/D cGvHD: ORR 50% vs 26%, CR 7% vs 3%. #gvhdsm #bmtsm

[Jerfiz @Jerfiz1]

@Brianhemophilia Cool! Thanks for sharing- a very important observation from the study.

[Brian O Mahony @Brianhemophilia]

This is a very nice graphical representation of data from the HOPE-B Phase 3 clinical trial of AMT-061 showing the range of FIX expression at 26 weeks. This slide was not included in the late breaking session on HOPE-B at ASH. I saw it on on a tweet for their investor webinar

[Jerfiz @Jerfiz1]

Recently, after reading the list of COVID-19-related sanitization steps taken by my favorite hotel chain I though to myself “You were not doing these already? -Ugh”
If there is one thing positive about COVID-19, it’s the heightened (common-sense) cleaning of shared space.

[Jerfiz @Jerfiz1]

For all of the "singularity" enthusiast out there!

#coolpics #blackhole #singularity #scienceiscool
https://t.co/uabcYlxQIr

[Jerfiz @Jerfiz1]

Found this interesting Egyptian papyrus and was wondering if anybody here knows what it means. Feel free to share. #share #papyrus #walklikeanegyptian

[Jerfiz @Jerfiz1]

@nytimes @VincentRK No such thing as a free COVID-19 test!

[Jerfiz @Jerfiz1]

Invigorating debate at #soho2020 between Dr. Mateos and Dr. @ADispenzieri on whether to treat smouldering #myeloma with conclusions ultimately boiling-down to long-term benefits/AEs (>10 yrs) of limited-duration treatment based on risk-stratification and pt age + Tx goals.

[Jerfiz @Jerfiz1]

Great presentation from @LipeBrea, MD at #soho2020 Virtual meeting summarizing"risk-adapted therapy in elderly/frail/high-risk pts with MM"discussing the various treatment possibilities using existing treatment modalities, ultimately impinging on "goal of therapy"
#MYELOM